+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07734844

Randomized Study Comparing Intravitreal Tabirafusp Tedromer 5 mg to Aflibercept 2 mg for Visual Impairment in Diabetic Macular Edema

Led by Kodiak Sciences Inc · Updated on 2026-11-03

910

Participants Needed

52

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and effectiveness of tabirafusp tedromer compared to aflibercept in people with diabetic macular edema DME, a condition causing vision impairment related to diabetes. This phase 3 randomized trial aims to evaluate these two treatments administered by injection into the eye, focusing on improving vision clarity. Participants receive intravitreal injections of either tabirafusp tedromer or aflibercept. Tabirafusp tedromer is given once every 4 weeks for six doses, then either every 8 weeks or individualized between every 4 to 24 weeks depending on the group. Aflibercept is administered every 4 weeks for five doses, followed by every 8 weeks. The study compares these dosing schedules over time to assess treatment impact. During the trial, participants undergo regular eye exams to measure best corrected visual acuity at week 52 and other safety assessments. The study includes monitoring of treatment effects and side effects through scheduled visits with injections and vision tests. Participation lasts through the treatment and evaluation period, allowing researchers to gather data on vision changes and overall safety.

CONDITIONS

Brief Title

A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO

Research Team

K

Kodiak Sciences Inc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here